Precision Optics Shifts Focus to Manufacturing, Launches Unity Platform

TL;DR

**POCI's bet on its Unity platform and manufacturing scale-up is a high-stakes play, but customer concentration makes it a risky bet for growth.**

AI Summary

PRECISION OPTICS CORPORATION, INC. (POCI) reported a shift in its business mix for the fiscal year ended June 30, 2025, with systems manufacturing increasing to 43% of revenue from 19% in 2024, and engineering services decreasing to 26% from 45%. Ross Optical contributed 20% of revenue, down from 22%, and the micro-optics laboratory accounted for 11%, down from 14%. The company launched its Unity Imaging Platform in January 2025, a modular CMOS endoscopic system designed to accelerate time to market for medical imaging devices. POCI continues to focus on advanced optical instruments for medical devices and defense/aerospace, leveraging its Microprecision optics technology for smaller, disposable endoscopes. The company faces significant customer concentration risk, with two customers accounting for 22% and 20% of total revenues in fiscal year 2025, and 32.1% and 17.9% of total receivables. POCI employs 90 full-time individuals and holds patents expiring through March 2043, including for micro medical cameras.

Why It Matters

POCI's strategic pivot towards systems manufacturing and the launch of its Unity Imaging Platform could significantly impact its market position in the competitive medical device and defense/aerospace optics sectors. For investors, the successful transition of engineering design projects to higher-volume production, as anticipated by management, is crucial for revenue growth and profitability. Employees may see increased demand for manufacturing expertise, while customers could benefit from faster development cycles and more cost-effective, high-quality micro-optical solutions, particularly in single-use medical devices. However, the high customer concentration, with two customers representing 42% of 2025 revenue, poses a substantial risk, making POCI vulnerable to competitive pressures from larger industry players.

Risk Assessment

Risk Level: high — POCI faces high risk due to significant customer concentration, with two customers accounting for 22% and 20% of total revenues in fiscal year 2025, and 32.1% and 17.9% of total receivables. The loss of either of these customers would have a material impact on the business. Additionally, the company operates in highly competitive markets against larger competitors with substantially greater resources.

Analyst Insight

Investors should closely monitor POCI's customer diversification efforts and the adoption rate of its Unity Imaging Platform. Evaluate the company's ability to convert engineering projects into sustained production orders to mitigate the current customer concentration risk and drive long-term revenue growth.

Financial Highlights

debt To Equity

N/A

revenue

$23,911,000

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $23,911,000 — Aggregate market value of non-affiliate common stock (Calculated on December 31, 2024, based on 4,960,885 shares at $4.82 per share.)
• 7,714,701 — Shares of outstanding common stock (As of September 20, 2025.)
• 43% — Revenue from systems manufacturing (Increased from 19% in fiscal year 2024, indicating a strategic shift.)
• 26% — Revenue from engineering services (Decreased from 45% in fiscal year 2024, reflecting a transition from design to production.)
• 20% — Revenue from Ross Optical (Contribution to total revenues in fiscal year 2025.)
• 11% — Revenue from micro-optics laboratory (Contribution to total revenues in fiscal year 2025.)
• 90 — Total employees (As of June 30, 2025, all full-time.)
• 278 — Total customers (Served during fiscal year ending June 30, 2025.)
• 22% — Revenue from largest customer (One customer accounted for 22% of total revenues in fiscal year 2025.)
• 20% — Revenue from second largest customer (Another customer accounted for 20% of total revenues in fiscal year 2025.)

Key Players & Entities

• PRECISION OPTICS CORPORATION, INC. (company) — registrant
• POCI (company) — trading symbol
• Nasdaq Stock Market LLC (regulator) — exchange where common stock is registered
• Ross Optical Industries, Inc. (company) — acquired operating assets
• Lighthouse Imaging, LLC (company) — acquired operating assets
• SCHOTT North America, Inc. (company) — principal supplier of optical glass
• Ohara Corporation (company) — principal supplier of optical glass
• OmniVision Technologies, Inc. (company) — supplier of CMOS sensors
• December 31, 2024 (date) — date for market value calculation
• June 30, 2025 (date) — fiscal year end

FAQ

Risk Factors

• Customer Concentration [high — financial]: The company faces significant customer concentration risk, with two customers accounting for 22% and 20% of total revenues in fiscal year 2025. These same customers also represent 22% and 20% of total receivables, increasing financial vulnerability if either customer reduces business or defaults.
• Dependence on Medical and Defense Markets [medium — market]: POCI operates primarily in the medical device and defense/aerospace markets. Downturns or shifts in demand within these specific sectors, driven by regulatory changes, technological obsolescence, or geopolitical events, could materially impact revenue and profitability.
• Reliance on Proprietary Technology [medium — operational]: The company's competitive advantage relies on its proprietary optical and imaging technology, including patents for micro medical cameras expiring through March 2043. Failure to innovate or protect intellectual property could lead to loss of market share.
• Supply Chain and Manufacturing Complexity [medium — operational]: The company handles high complexity components and advanced manufacturing challenges. Disruptions in the supply chain for specialized optical components or issues in the manufacturing process for intricate systems could lead to production delays and impact customer satisfaction.
• Competition in Imaging Technology [medium — market]: The market for advanced optical instruments, particularly in medical imaging, is competitive. The success of new products like the Unity Imaging Platform depends on its ability to gain market traction against established and emerging competitors.

Industry Context

Precision Optics Corporation operates in the specialized field of advanced optical instruments, primarily serving the medical device and defense/aerospace sectors. The medical imaging market is characterized by rapid technological advancement, a growing demand for minimally invasive procedures, and increasing adoption of disposable devices. In defense and aerospace, there is a continuous need for high-performance optical solutions for applications like satellite communications. Key trends include miniaturization, enhanced imaging capabilities (e.g., higher resolution, better illumination), and integration of digital technologies like CMOS sensors.

Regulatory Implications

The medical device sector is heavily regulated by bodies like the FDA. POCI's focus on medical imaging instruments means compliance with stringent quality standards (e.g., ISO 13485) and regulatory pathways for new device approvals is critical. Any changes in medical device regulations or standards could impact product development timelines and market access.

What Investors Should Do

1. Monitor customer concentration risk
2. Evaluate the success of the Unity Imaging Platform
3. Assess the sustainability of the systems manufacturing shift
4. Track patent portfolio and R&D investment

Key Dates

• 2025-01-01: Launch of Unity Imaging Platform — Introduced a modular CMOS endoscopic system designed to accelerate time to market for medical imaging devices, potentially driving future revenue growth.
• 2024-12-31: Market Capitalization Calculation — Aggregate market value of non-affiliate common stock was $23,911,000, based on 4,960,885 shares at $4.82 per share, indicating the company's valuation at that point.
• 2025-06-30: Fiscal Year End — Reported significant shift in business mix towards systems manufacturing and noted 90 full-time employees.
• 2025-09-20: Shares Outstanding Record — 7,714,701 shares of common stock were outstanding, providing a basis for per-share metrics and ownership analysis.
• 2043-03-01: Patent Expiration (example) — Indicates the long-term nature of the company's intellectual property protection, with key patents for micro medical cameras extending to this date.

Glossary

CMOS sensor technology

Complementary Metal-Oxide-Semiconductor, a type of image sensor technology commonly used in digital cameras and imaging devices. (Key technology behind the new Unity Imaging Platform, enabling smaller and potentially more cost-effective medical imaging devices.)

Endoscope

A medical instrument used to examine the interior of a hollow organ or cavity, typically equipped with a light and a camera. (Core product area for POCI, with a focus on developing smaller, disposable, and enhanced imaging systems for minimally invasive surgery.)

Microprecision optics

Extremely small and precisely manufactured optical components and assemblies. (POCI leverages this technology to create advanced, miniaturized optical solutions for medical and defense applications.)

Systems Manufacturing

The process of assembling and producing complete optical and imaging systems for customers. (This segment has significantly increased its revenue contribution, indicating a strategic shift for POCI towards higher-volume production.)

Engineering and Product Development

The process of designing new devices, solving customer needs, and creating manufacturing processes. (This segment's revenue share has decreased, aligning with the company's move from design services to manufacturing.)

Year-Over-Year Comparison

Precision Optics Corporation, Inc. has undergone a significant strategic shift, evidenced by the substantial increase in revenue from systems manufacturing to 43% (up from 19% in FY2024) and a corresponding decrease in engineering services revenue to 26% (down from 45%). While Ross Optical and the micro-optics laboratory saw minor declines in their revenue share, the overall business mix has clearly moved towards production. The company also launched its Unity Imaging Platform, indicating a focus on new product development. However, the filing highlights persistent customer concentration risks, with key customers still representing substantial portions of revenue and receivables, a factor that likely carried over from the previous year.

Key Financial Figures

• $0.01 — nge on which registered Common stock, $0.01 par value POCI Nasdaq Stock Market
• $4.82 — s on such date, at the closing price of $4.82 per share, as reported on Nasdaq on Dec

Filing Documents

• poci_i10k-063025.htm (10-K) — 708KB
• poci_ex2301.htm (EX-23.1) — 3KB
• poci_ex3101.htm (EX-31.1) — 10KB
• poci_ex3102.htm (EX-31.2) — 12KB
• poci_ex3201.htm (EX-32.1) — 5KB
• 0001683168-25-007305.txt ( ) — 4273KB
• poci-20250630.xsd (EX-101.SCH) — 25KB
• poci-20250630_cal.xml (EX-101.CAL) — 51KB
• poci-20250630_def.xml (EX-101.DEF) — 107KB
• poci-20250630_lab.xml (EX-101.LAB) — 332KB
• poci-20250630_pre.xml (EX-101.PRE) — 259KB
• poci_i10k-063025_htm.xml (XML) — 497KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 6 Item 1B. Unresolved Staff Comments 14 Item 1C. Cybersecurity 15 Item 2.

Properties

Properties 16 Item 3.

Legal Proceedings

Legal Proceedings 17 Item 4. Mine Safety Disclosures 17 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 18 Item 6. [Reserved] 18 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 21 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 22 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 23 Item 9A.

Controls and Procedures

Controls and Procedures 23 Item 9B. Other Information 23 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 23 PART III Item 10. Directors, Executive Officers and Corporate Governance 24 Item 11.

Executive Compensation

Executive Compensation 24 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 24 Item 13. Certain Relationships and Related Transactions, and Director Independence 24 Item 14. Principal Accounting Fees and Services 24 PART IV Item 15. Exhibits, Financial Statement Schedules 25 Item 16. Form 10-K Summary 28

Signatures

Signatures 29 i PART I This Annual Report contains forward-looking Report on Form 10-K regarding our financial performance, business strategy and plans and objectives of management for future operations and any other future events are forward-looking statements and based on our beliefs and assumptions. When used in this report, the words "anticipate," "suggest," "estimate," "plan," "project," "continue," "ongoing," "potential," "expect," "predict," "believe," "intend," "may," "will," "should," "could," "would" and other similar words are one way to identify such forward-looking statements. You should not place undue reliance on these forward-looking statements. Actual results could vary materially from these forward-looking statements. Such statements reflect our current view with respect to future events and are subject to certain risks, uncertainties, and assumptions including, without limitation, those risks and uncertainties contained in the Risk Factors section of this Annual Report on Form 10-K and our other filings made with the SEC. Although we believe that our expectations are reasonable, we can give no assurance that such expectations will prove to be correct. Based upon changing conditions, any one or more of these events described herein as anticipated, believed, estimated, expected or intended may not occur. All prior and subsequent written and oral forward-looking statements attributable to our Company or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement. We do not intend to update any of the forward-looking statements after the date of this Annual Report to conform these statements to actual results or to changes in our expectations, except as required by law.

BUSINESS

ITEM 1. BUSINESS. Overview We have been a developer and manufacturer of advanced optical instruments since 1982, and we operate primarily in two key market segments: medical devices and advanced defense/aerospace products. Within our proprietary optical and imaging technology, our unique custom designs, expert manufacturing capabilities, and advanced engineering and development capabilities have generated traditional endoscopes and endocouplers, digital imaging endoscopes using CMOS sensor technology, some designed and manufactured for single-use, as well as other, more advanced, custom imaging and illumination products for our customers' use in minimally invasive surgical procedures. We design and manufacture ultra-high precision endoscopes and very small Microprecision lenses, assemblies and complete medical devices to meet the surgical community's continuing demand for smaller, disposable, and more enhanced imaging systems for minimally invasive surgery. We also apply our unique technologies to applications in the Defense / Aerospace markets including applications supporting satellite network communications. To support these two critical market categories, our business operations are conducted in four areas: systems manufacturing, engineering and product development, Ross Optical components and assemblies, and our micro-optics laboratory. Our systems manufacturing operations assemble and manufacture components and systems for both medical device and advanced aerospace customers who choose to outsource these services based on our ability to handle high complexity components, specific optical technologies, micro-optical assemblies and other advanced manufacturing challenges. Our engineering and product development team assesses specific customer product needs, designs devices to solve those needs, and creates manufacturing processes that enable higher volume production of these devices and assemblies that can then be executed by our manufacturing operations gr

View Full Filing

View this 10-K filing on SEC EDGAR